Gilead Sciences Signs New Joint Procurement Agreement with the European Commission for Veklury® (Remdesivir)Business Wire • 07/19/22
Gilead Sciences to Release Second Quarter 2022 Financial Results on Tuesday, August 2, 2022Business Wire • 07/12/22
Gilead Sciences Appoints Deborah Telman as Executive Vice President, Corporate Affairs and General CounselBusiness Wire • 07/12/22
Kite's CAR T-cell Therapy Yescarta® Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Follicular LymphomaBusiness Wire • 06/28/22
Gilead Resubmits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting HIV-1 Capsid InhibitorBusiness Wire • 06/27/22
Gilead Endorses The Kigali Declaration On Preventing, Controlling and Eliminating Neglected Tropical DiseasesBusiness Wire • 06/27/22
Investigational Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug Resistant HIVBusiness Wire • 06/24/22
Treatment With Hepcludex® (Bulevirtide) Meets Primary Endpoint and Achieves Significant Response in Chronic Hepatitis Delta Virus at 48 WeeksBusiness Wire • 06/23/22
Gilead to Present Latest Data From Across Liver Disease Development Programs at the International Liver Congress™ 2022Business Wire • 06/21/22